Healthy AgingCBD-MAPNCT07910292
Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot Study
A study testing Cannabidiol (CBD) in people with Healthy Aging and Cognition, run by Medical University of Silesia.
Trial summary
This pilot study aims to investigate the effects of a single oral dose of cannabidiol (CBD) on memory and attention in healthy adults aged 60 to 70 years. CBD is a naturally occurring compound found in cannabis that does not produce the intoxicating effects associated with THC. Read more about this study
- Who is it for?
- Ages 60 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Aging, Cognition
- What is being tested?
- Cannabidiol (CBD)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Nov 2026to 30 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age between 60 and 70 years.
- No significant cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score >26.
- Not currently using cannabinoids.
- Body mass index (BMI) between 18 and 30 kg/m².
Who cannot join
- Severe cardiovascular diseases (heart failure, coronary artery disease, advanced hypertension, previous myocardial infarction) or respiratory diseases (chronic obstructive pulmonary disease [COPD], severe bronchial asthma, pulmonary fibrosis).
- History of substance abuse.
- Current or chronic somatic disorders.
- History of severe psychiatric or neurological disorders (schizophrenia, bipolar disorder, severe depression requiring hospitalization, or neurological diseases such as epilepsy, Parkinson's disease, multiple sclerosis, or brain injuries resulting in permanent cognitive deficits).
- Use of medications that may have clinically significant interactions with cannabidiol, particularly medications metabolized by the cytochrome P450 system, such as antiepileptic drugs, anticoagulants, and some antidepressants and antipsychotics.
- Substance use: smoking more than 5 cigarettes per day or use of CBD/THC within 30 days before the study (positive urine test for THC).
- Inability to comply with study procedures.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70 Years: A Pilot Study
This pilot study aims to investigate the effects of a single oral dose of cannabidiol (CBD) on memory and attention in healthy adults aged 60 to 70 years. CBD is a naturally occurring compound found in cannabis that does not produce the intoxicating effects associated with THC.
The main research question is whether CBD can improve episodic memory (the ability to remember previously learned information), working memory (the ability to temporarily hold and use information), and attention compared with placebo.
Read more
The researchers hypothesize that participants will perform better on memory and attention tasks after receiving CBD than after receiving placebo.
The study will involve approximately 50 healthy adults aged 60 to 70 years. Each participant will attend two study sessions, scheduled 14 to 30 days apart. During one session, participants will receive a single oral dose of 25 mg CBD, while during the other session, they will receive a placebo capsule containing no CBD. The order of administration will be randomly assigned, and neither the participants nor the researchers assessing their performance will know which capsule was administered during each session.
Memory and attention will be evaluated using standardized memory tests and computer-based cognitive tasks. The findings will provide preliminary evidence on the potential effects of CBD on cognitive functioning in older adults.
- Conditions
- Healthy Aging, Cognition
- Being tested
- Cannabidiol (CBD), Placebo
- Keywords
- Cannabidiol, Episodic Memory, Working Memory, Attention, Healthy Aging, CBD, Cognitive Function
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cannabidiol (CBD)Dietary supplement
Single oral administration of a softgel capsule containing 25 mg of cannabidiol (CBD). Each participant will receive CBD during one of the two experimental sessions, according to the randomized treatment sequence.
PlaceboDietary supplement
Single oral administration of a placebo softgel capsule containing medium-chain triglyceride (MCT) oil only. The placebo capsules will be visually indistinguishable from the CBD capsules. Each participant will receive placebo during one of the two experimental sessions, according to the randomized treatment sequence.
| Study group | Role | What they receive |
|---|---|---|
| CBD/Placebo | Experimental | This group will receive CBD during the first study session and placebo during the second study session, following a washout period of 14-30 days. Receives: Dietary Supplement: Cannabidiol (CBD); Dietary Supplement: Placebo |
| Placebo/CBD | Experimental | This group will receive placebo during the first study session and CBD during the second study session, following a washout period of 14-30 days. Receives: Dietary Supplement: Cannabidiol (CBD); Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Verbal Episodic Memory - RAVLT Delayed Free Recall
Verbal episodic memory will be assessed using the Rey Auditory Verbal Learning Test (RAVLT). Participants will be presented with a list of 15 unrelated words over five learning trials, followed by an interference list and delayed recall assessments. The outcome measure will be the number of correctly recalled words during the second delayed free recall assessment, approximately 120 minutes after administration of CBD or placebo. Scores range from 0 to 15, with higher scores indicating better memory performance.
Measured: Approximately 120 minutes after administration of CBD or placebo, during each of the two study sessions.
Secondary outcomes (2)
Working Memory - 2-Back Task Accuracy
Working memory will be assessed using a computerized visual 2-back task with emotionally neutral stimuli. Participants will indicate whether the currently presented stimulus matches the stimulus presented two positions earlier. Performance will be measured as the percentage of correct responses, ranging from 0% to 100%, with higher scores indicating better working memory performance.
Measured: During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions.
Attention - 0-Back Task Accuracy
Attention will be assessed using a computerized visual 0-back task with emotionally neutral stimuli. Participants will respond to the presentation of a predefined target stimulus. Performance will be measured as the percentage of correct responses, ranging from 0% to 100%, with higher scores indicating better attention performance.
Measured: During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study startNov 2026 (estimated)
- Primary completion30 Mar 2027 (estimated)
- Study completion30 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Silesia
- Sponsor type
- University, hospital or other
- Collaborators
- Humanitas University
- Responsible party
- Principal investigator, Gniewko Więckiewicz, Medical University of Silesia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07910292
- Sponsor's protocol ID
- CBD-MAP-6070
- Other IDs
- 2024/08/X/HS6/01383
- Acronym
- CBD-MAP
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70 Years: A Pilot Study
- ClinicalTrials.gov ID
- NCT07910292
- Acronym / sponsor ID
- CBD-MAP / CBD-MAP-6070
- Conditions
- Healthy Aging, Cognition
- Keywords
- Cannabidiol, Episodic Memory, Working Memory, Attention, Healthy Aging, CBD, Cognitive Function
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Medical University of SilesiaUniversity, hospital or other
- Collaborators
- Humanitas University
- Study start
- Nov 2026 (estimated)
- Primary completion
- 30 Mar 2027 (estimated)
- Study completion
- 30 Mar 2027 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study aims to investigate the effects of a single oral dose of cannabidiol (CBD) on memory and attention in healthy adults aged 60 to 70 years. CBD is a naturally occurring compound found in cannabis that does not produce the intoxicating effects associated with THC.
The main research question is whether CBD can improve episodic memory (the ability to remember previously learned information), working memory (the ability to temporarily hold and use information), and attention compared with placebo.
The researchers hypothesize that participants will perform better on memory and attention tasks after receiving CBD than after receiving placebo.
The study will involve approximately 50 healthy adults aged 60 to 70 years. Each participant will attend two study sessions, scheduled 14 to 30 days apart. During one session, participants will receive a single oral dose of 25 mg CBD, while during the other session, they will receive a placebo capsule containing no CBD. The order of administration will be randomly assigned, and neither the participants nor the researchers assessing their performance will know which capsule was administered during each session.
Memory and attention will be evaluated using standardized memory tests and computer-based cognitive tasks. The findings will provide preliminary evidence on the potential effects of CBD on cognitive functioning in older adults.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CBD/Placebo | Experimental | Dietary Supplement: Cannabidiol (CBD), Dietary Supplement: PlaceboThis group will receive CBD during the first study session and placebo during the second study session, following a washout period of 14-30 days. |
| Placebo/CBD | Experimental | Dietary Supplement: Cannabidiol (CBD), Dietary Supplement: PlaceboThis group will receive placebo during the first study session and CBD during the second study session, following a washout period of 14-30 days. |
Who may qualify
- Ages
- 60 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age between 60 and 70 years.
- No significant cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score >26.
- Not currently using cannabinoids.
- Body mass index (BMI) between 18 and 30 kg/m².
Key exclusion criteria (7 listed)
- Severe cardiovascular diseases (heart failure, coronary artery disease, advanced hypertension, previous myocardial infarction) or respiratory diseases (chronic obstructive pulmonary disease [COPD], severe bronchial asthma, pulmonary fibrosis).
- History of substance abuse.
- Current or chronic somatic disorders.
- History of severe psychiatric or neurological disorders (schizophrenia, bipolar disorder, severe depression requiring hospitalization, or neurological diseases such as epilepsy, Parkinson's disease, multiple sclerosis, or brain injuries resulting in permanent cognitive deficits).
- Use of medications that may have clinically significant interactions with cannabidiol, particularly medications metabolized by the cytochrome P450 system, such as antiepileptic drugs, anticoagulants, and some antidepressants and antipsychotics.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cannabidiol (CBD)Single oral administration of a softgel capsule containing 25 mg of cannabidiol (CBD). Each participant will receive CBD during one of the two experimental sessions, according to the randomized treatment sequence. | Dietary supplement | CBD/Placebo, Placebo/CBD |
| PlaceboSingle oral administration of a placebo softgel capsule containing medium-chain triglyceride (MCT) oil only. The placebo capsules will be visually indistinguishable from the CBD capsules. Each participant will receive placebo during one of the two experimental sessions, according to the randomized treatment sequence. | Dietary supplement | CBD/Placebo, Placebo/CBD |
Primary outcome
Verbal Episodic Memory - RAVLT Delayed Free Recall
Time frame: Approximately 120 minutes after administration of CBD or placebo, during each of the two study sessions.
Verbal episodic memory will be assessed using the Rey Auditory Verbal Learning Test (RAVLT). Participants will be presented with a list of 15 unrelated words over five learning trials, followed by an interference list and delayed recall assessments. The outcome measure will be the number of correctly recalled words during the second delayed free recall assessment, approximately 120 minutes after administration of CBD or placebo. Scores range from 0 to 15, with higher scores indicating better memory performance.
2 secondary outcomes
Working Memory - 2-Back Task Accuracy
Time frame: During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions.
Attention - 0-Back Task Accuracy
Time frame: During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Aging
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Recruiting
Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults
Healthy Aging
Recruiting
Effects of Breathing Exercises on Cognition in Older Adults
Older Adults (65 Years and Older), Cognition
Not yet recruiting
Eccentric Exercise in Community-dwelling Older Adults
Ageing Well
Recruiting
Aquatic Power Training Dosing Strategies and Creatine Supplementation in Older Adults
Aging, Supplementation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Cannabidiol (CBD) in people with Healthy Aging and Cognition, run by Medical University of Silesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alicja Anna Binkowska, PhD (+48 693 540 990, alicja.binkowska@humanitas.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Verbal Episodic Memory - RAVLT Delayed Free Recall (time frame: Approximately 120 minutes after administration of CBD or placebo, during each of the two study sessions.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.